Drugs / Polysaccharide superparamagnetic iron oxide
Polysaccharide superparamagnetic iron oxide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06010537 | Apr 2021 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06051565 | Nov 2021 → Jun 2022 | type 2 diabetes mellitus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polysaccharide superparamagnetic iron oxide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06051565 ↗ |
| Modality | Diagnostic / imaging agent | “Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.” NCT06010537 ↗ |
| Route | Intravenous | “Intravenous injected polysaccharide superparamagnetic iron oxide injection at 2.5 mg/kg dose;” NCT06010537 ↗ |